{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T12:21:50Z","timestamp":1697372510844},"reference-count":31,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            It is well acknowledged that ansamycins display immunosuppressive and anti-inflammatory properties in vitro and in vivo. Rifalazil, a new ansamycin derivative, has not been studied in the context of inflammation. In particular, there are no data on the possible interference of rifalazil with oxidant production by phagocytes. We have compared the antioxidant properties of rifalazil to those of rifampin, a drug well known in this context, by using cellular and acellular oxidant-generating systems. Oxidant production by polymorphonuclear neutrophils was measured in terms of cytochrome\n            <jats:italic>c<\/jats:italic>\n            reduction, lucigenin-amplified chemiluminescence (Lu-ACL), and the 2\u2032,7\u2032-dichlorofluorescin diacetate H\n            <jats:sub>2<\/jats:sub>\n            (DCFDA-H\n            <jats:sub>2<\/jats:sub>\n            ) technique (intracellular oxidant production). Rifalazil impaired O\n            <jats:sub>2<\/jats:sub>\n            <jats:sup>\u2212<\/jats:sup>\n            production in a concentration-dependent manner, with 50% inhibitory concentrations (IC\n            <jats:sub>50<\/jats:sub>\n            ) (concentrations which inhibit 50% of the response) of 5.4 (30 and 60 min of incubation) and 6.4 (30 min) mg\/liter, respectively, for phorbol myristate acetate (PMA) and formyl-methionyl-leucyl-phenylalanine (fMLP) stimulation. In agreement with the published fMLP-like activity of rifampin, the inhibitory effect of rifampin was significantly greater for fMLP (IC\n            <jats:sub>50<\/jats:sub>\n            of 5.6 mg\/liter) than for PMA (IC\n            <jats:sub>50<\/jats:sub>\n            of 58 mg\/liter) stimulation. Alteration of intracellular oxidant production was also observed with IC\n            <jats:sub>50<\/jats:sub>\n            values similar to those obtained by the cytochrome assay. In addition, rifalazil and rifampin (\u226525 mg\/liter) scavenged O\n            <jats:sub>2<\/jats:sub>\n            <jats:sup>\u2212<\/jats:sup>\n            , as demonstrated by the acellular (hypoxanthine-xanthine oxidase) system. Interference with light detection systems was evidenced for both drugs by Lu-ACL. The clinical relevance of the antioxidant effect of rifalazil demonstrated in vitro, in particular its potential anti-inflammatory activity, requires further investigation.\n          <\/jats:p>","DOI":"10.1128\/aac.49.12.5018-5023.2005","type":"journal-article","created":{"date-parts":[[2005,11,22]],"date-time":"2005-11-22T21:57:58Z","timestamp":1132696678000},"page":"5018-5023","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Interaction of Rifalazil with Oxidant-Generating Systems of Human Polymorphonuclear Neutrophils"],"prefix":"10.1128","volume":"49","author":[{"given":"M. T.","family":"Labro","sequence":"first","affiliation":[{"name":"INSERM U479"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ollivier","sequence":"additional","affiliation":[{"name":"INSERM U698, CHU Xavier Bichat, 16 rue Henri Huchard, 75018 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Babin-Chevaye","sequence":"additional","affiliation":[{"name":"INSERM U479"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/abbi.1999.1215","volume":"366","year":"1999","unstructured":"Afanas\u2032ev, I. B., E. A. Ostrachovitch, and L. G. Korkina. 1999. Lucigenin is a mediator of cytochrome c reduction but not of superoxide production. Arch. Biochem. Biophys.366:267-274.","journal-title":"Arch. Biochem. Biophys."},{"key":"e_1_3_2_3_2","first-page":"357","volume":"92","year":"1984","unstructured":"Aniansson, H., O. Stendhal, and C. Dahlgren. 1984. Comparison between luminol- and lucigenin-dependent chemiluminescence of polymorphonuclear leukocytes. Acta Pathol. Microbiol. Immunol. Scand. Sect. C92:357-361.","journal-title":"Acta Pathol. Microbiol. Immunol. Scand. Sect. C"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/mdr.1997.3.277","volume":"3","year":"1997","unstructured":"Bermudez, L. E., and C. B. Inderlied. 1997. Effect of Mycobacterium avium infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages. Microb. Drug Resist.3:277-282.","journal-title":"Microb. Drug Resist."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/315518"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1172\/JCI109007","volume":"61","year":"1978","unstructured":"Cohen, H. J., and M. E. Chovaniec. 1978. Superoxide generation by digitonin-stimulated guinea-pig granulocytes. J. Clin. Investig.61:1081-1087.","journal-title":"J. Clin. Investig."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0891-5849(90)90147-B","volume":"8","year":"1990","unstructured":"Cross, A. R. 1990. Inhibitors of the leukocyte superoxide generating oxidase: mechanisms of action and methods for their elucidation. Free Radic. Biol. Med.8:71-93.","journal-title":"Free Radic. Biol. Med."},{"key":"e_1_3_2_8_2","first-page":"257","volume":"41","year":"1995","unstructured":"Demkow, U., W. Malkowska-Zwierz, E. Rogala, E. Skopinska-Rozewska, and Z. Lewandowski. 1995. Effect of antituberculous drugs, isoniazid, pyrazinamide and rifampicin, on chemiluminescence of the human polymorphonuclear leukocytes. Folia Biol. (Prague)41:257-262.","journal-title":"Folia Biol. (Prague)"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.1972-1976.2001"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.24.5.777"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3181\/00379727-181-42250","volume":"181","year":"1986","unstructured":"Gray, G. D., and G. M. Ohlmann. 1986. Countergradients of nonchemotactic ligands for N-formylmethionylleucylphenylalanine (FMLP) receptors promote FMLP-induced chemotaxis. Proc. Soc. Exp. Biol. Med.181:256-262.","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(03)00109-2"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.5.667"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2749"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.4.615"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/14787210.3.1.91","volume":"3","year":"2005","unstructured":"Labro, M. T. 2005. Antiinflammatory activity of ansamycins. Expert Rev. Anti-Infect. Ther.3:91-103.","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"e_1_3_2_17_2","first-page":"85","year":"2004","unstructured":"Labro, M. T. 2004. Antibacterial agents and the oxidative burst, p. 85-106. In B. K. Rubin and J. Tamaoki (ed.), Antibiotics as anti-inflammatory and immunomodulatory agents. Birkh\u00e4user Verlag AG, Basel, Switzerland.","journal-title":"Antibiotics as anti-inflammatory and immunomodulatory agents"},{"key":"e_1_3_2_18_2","first-page":"953","year":"1993","unstructured":"Labro, M. T., and J. El Benna. 1993. Interaction of antibiotics with the phagocyte oxidative burst, p. 953-964. In E. Faist, J. L. Meakins, and F. W. Schildberg (ed.), Host defense dysfunction in trauma, shock and sepsis. Springer-Verlag, Berlin, Germany.","journal-title":"Host defense dysfunction in trauma, shock and sepsis"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01534392","volume":"19","year":"1995","unstructured":"Miesel, R., D. Sanocka, M. Kurpisz, and H. Kr\u00f6ger. 1995. Antiinflammatory effects of NADPH oxidase inhibitors. Inflammation19:347-362.","journal-title":"Inflammation"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0006-2952(03)00083-2","volume":"65","year":"2003","unstructured":"Myhre, O., J. M. Andersen, H. Aarnes, and F. Fonnum. 2003. Evaluation of the probes 2\u2032,7\u2032-dichlorofluorescein diacetate, luminol, and lucigenin as indicators of reactive species formation. Biochem. Pharmacol.65:1575-1582.","journal-title":"Biochem. Pharmacol."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1989.tb00814.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1009499210857","volume":"10","year":"2000","unstructured":"Plantin-Carrenard, E., F. Braut-Boucher, M. Bernard, C. Derappe, M. J. Foglietti, and M. Aubery. 2000. Fluorogenic probes applied to the study of induced oxidative stress in the human leukaemia HL 60 cell line. J. Fluoresc.10:167-176.","journal-title":"J. Fluoresc."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1135-1136.2003"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2003.09.009"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"A495","DOI":"10.1164\/ajrccm.159.2.9804061","volume":"159","year":"1999","unstructured":"Rose, L. M., M. K. Vasiljev, P. Adams, V. Mizuno, C. Wells, and A. B. Montgomery. 1999. Safety and pharmacokinetics of PA-1648, a new rifamycin in normal volunteers. Am. J. Respir. Crit. Care Med.159(Suppl.):A495.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.2.255"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/03009748209098164","volume":"11","year":"1982","unstructured":"Spisani, S., L. Dovigo, G. Corazza, R. Carletti, and S. Traniello. 1982. The effect of rifamycin SV on neutrophil functions in patients with rheumatoid arthritis. Scand. J. Rheumatol.11:65-69.","journal-title":"Scand. J. Rheumatol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1027314419843","volume":"21","year":"1997","unstructured":"Spisani, S., S. Traniello, C. Martuccio, O. Rizzuti, and L. Cellai. 1997. Rifamycins inhibit human neutrophil functions: new derivatives with potential antiinflammatory activity. Inflammation21:391-400.","journal-title":"Inflammation"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/A:1022341909396","volume":"22","year":"1998","unstructured":"Spisani, S., S. Traniello, A. M. Onori, O. Rizzuti, C. Martuccio, and L. Cellai. 1998. 3-(Carboxyalkylthio) rifamycin S and SV derivatives inhibit human neutrophil functions. Inflammation22:459-469.","journal-title":"Inflammation"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-002-8520-9"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/10715769709097783","volume":"26","year":"1997","unstructured":"Whiteman, M., and B. Halliwell. 1997. Prevention of peroxynitrite-dependent tyrosine titration and inactivation of alpha1 antiproteinase by antibiotics. Free Radic. Res.26:49-56.","journal-title":"Free Radic. Res."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000238548","volume":"34","year":"1988","unstructured":"Zeis, B. M. 1988. Antimycobacterial drugs and the production of reactive oxidants by polymorphonuclear leucocytes in vitro. Chemotherapy34:56-60.","journal-title":"Chemotherapy"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.12.5018-5023.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.12.5018-5023.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:33:40Z","timestamp":1645468420000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.12.5018-5023.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1128\/AAC.49.12.5018-5023.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.12.5018-5023.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"2005-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-09-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}